Our core competitiveness arises from high-quality innovative products and marketing driven by robust clinical trials and evidence-based medicine. Our primary therapeutic area focus is cardiovascular and cerebrovascular disease, with active expansion into diabetes, oncology, orthopedics and infectious disease. Through in-house R&D, partnerships, strategic investments, and acquisitions, we are rapidly enriching our pipeline, developing multiple blockbuster products, and building a fully integrated pharmaceutical ecosystem. Guided by unified purpose and international expansion, we will continue to build our high-caliber team.

以优质创新产品和循证医学推广为核心竞争力；以心脑血管领域为龙头，拓展降血糖、抗肿瘤、骨科、抗感染等目标领域；通过自主研发、技术合作、投资并购，快速丰富创新产品管线，发展多个重磅产品，共建医药生态链；以集团化、国际化为导向，持续实现人才和管理升级。